Deutsche Numis Keeps Their Hold Rating on CureVac (CVAC)

In a report released on May 8, Emmanuel Papadakis from Deutsche Numis maintained a Hold rating on CureVac (CVAC – Research Report), with a price target of $6.50. The company’s shares closed yesterday at $2.98.

Papadakis covers the Healthcare sector, focusing on stocks such as BioNTech SE, Roche Holding AG, and Sanofi. According to TipRanks, Papadakis has an average return of 6.4% and a 58.58% success rate on recommended stocks.

In addition to Deutsche Numis, CureVac also received a Hold from Leerink Partners’s Mani Foroohar in a report issued on April 25. However, on April 26, UBS maintained a Buy rating on CureVac (NASDAQ: CVAC).

CVAC market cap is currently $667.2M and has a P/E ratio of -2.34.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CureVac (CVAC) Company Description:

CureVac BV a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company’s product portfolio includes clinical and preclinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in a Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2), for which the company initiated a Phase 1 clinical trial.